Affordable Access

Publisher Website

Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice

Authors
Journal
PLoS ONE
1932-6203
Publisher
Public Library of Science
Publication Date
Volume
7
Issue
12
Identifiers
DOI: 10.1371/journal.pone.0051485
Keywords
  • Research Article
  • Biology
  • Biochemistry
  • Drug Discovery
  • Biotechnology
  • Microbiology
  • Immunity
  • Immunotherapy
  • Virology
  • Animal Models Of Infection
  • Antivirals
  • Pathogenesis
  • Medicine
  • Anatomy And Physiology
  • Immune Physiology
  • Antibodies
  • Drugs And Devices
  • Drug Research And Development
  • Infectious Diseases
  • Viral Diseases
  • Respiratory Syncytial Virus Infection
  • Oncology
  • Cancer Treatment
  • Antibody Therapy
  • Physics
  • Biophysics
  • Cell Motility
Disciplines
  • Biology
  • Medicine

Abstract

Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of new therapeutics is high priority. Previous studies with a monoclonal antibody (mAb) reactive to an epitope proximal to the central conserved region (CCR) of RSV G protein (mAb 131-2G) showed therapeutic efficacy for reducing pulmonary inflammation RSV infection in BALB/c mice. Here, we show a protective effect in RSV-infected mice therapeutically treated with a mAb (130-6D) reactive to an epitope within the CCR of G protein, while treatment with a mAb specific for a carboxyl G protein epitope had no effect. Combined treatment with mAbs 130-6D and 131-2G significantly decreased RSV-associated pulmonary inflammation compared to either antibody alone. The results suggest that anti-RSV G protein mAbs that react at or near the CCR and can block RSV G protein-mediated activities are effective at preventing RSV disease and may be an effective strategy for RSV therapeutic treatment.

There are no comments yet on this publication. Be the first to share your thoughts.